Los Angeles Lifestyle & Leisure
American Shared Hospital Services Schedules First Quarter 2026 Financial Results Conference Call
American Shared Hospital Services announced it will release Q1 2026 financial results on May 14, 2026, followed by a conference call to discuss the results and provide updates on its cancer treatment services. Read the full article →
Top Stories
Lunai Bioworks Sues Alleged Naked Short Sellers for Securities Fraud
Versus Systems Leverages Gamification and Real-World Rewards to Boost Audience Engagement
BioStem Technologies to Present at 16th Annual LD Micro Invitational
IMA Worldwide Earns ACMP QEP Designation for Three CCMP-Approved AIM Programs
Heavenly's Lawn Care Expands Eco-Friendly Services to Four Orange County Cities
Biotech
Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities
SureNano Science Ltd., through its subsidiary GlucaPharm Inc., is developing GEP-44, a novel triple agonist peptide that could improve efficacy, toler...
Dogwood Therapeutics Reports First Quarter 2026 Results, Highlights Pipeline Progress for Halneuron and SP16
Dogwood Therapeutics announced Phase 2b data for Halneuron expected fall 2026 and FDA clearance for SP16 Phase 1b trial, with cash runway into Q4 2026...
LIXTE Biotechnology Reports First-Quarter Progress on Oncology Pipeline and Strategic Expansion
LIXTE Biotechnology announced first-quarter 2026 progress including expansion of its ovarian cancer trial for LB-100 and growth at its Liora Technolog...
NanoViricides Highlights Broad-Spectrum Antiviral Candidate NV-387 Amid Ebola Outbreak
NanoViricides emphasizes the potential of its broad-spectrum antiviral candidate NV-387 as a pandemic preparedness tool during the ongoing Bundibugyo ...
Quantum BioPharma Hits Midpoint Enrollment in MS Imaging Study, Showing Encouraging Preliminary Data
Quantum BioPharma reported that its collaborative multiple sclerosis imaging study with Massachusetts General Hospital has reached midpoint enrollment...
Lantern Pharma Gains FDA Support for HARMONIC Trial Amendments in Never-Smoker NSCLC
The FDA's non-objection to protocol amendments for Lantern Pharma's Phase 2 HARMONIC trial clarifies the regulatory path for LP-300 in never-smokers w...
Telomir Pharmaceuticals Reports Preclinical Data Supporting Telomir-Zn in Wilson's Disease
Telomir Pharmaceuticals announced peer-reviewed preclinical data showing Telomir-Zn improves survival and reduces oxidative stress in a Wilson's disea...
SureNano Science Ltd. Enters GLP-1 Race with Novel Peptide GEP-44
SureNano Science Ltd. is advancing GEP-44, a novel GLP-1 peptide for obesity, positioning itself as an agile player in the booming GLP-1 therapy marke...